These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 25428265)

  • 1. Tailored antiplatelet therapy in a patient with ITP and clopidogrel resistance.
    Mendolicchio GL; Zavalloni D; Bacci M; Roveda M; Quagliuolo V; Anselmi CV; Rota LL; Ruggeri ZM
    Thromb Haemost; 2015 Mar; 113(3):664-7. PubMed ID: 25428265
    [No Abstract]   [Full Text] [Related]  

  • 2. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.
    Mayer K; Schulz S; Bernlochner I; Morath T; Braun S; Hausleiter J; Massberg S; Schunkert H; Laugwitz KL; Kastrati A; Sibbing D
    Thromb Haemost; 2014 Aug; 112(2):342-51. PubMed ID: 24718389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry.
    Orban M; Mayer K; Morath T; Bernlochner I; Hadamitzky M; Braun S; Schulz S; Hoppmann P; Hausleiter J; Tiroch K; Mehilli J; Schunkert H; Massberg S; Laugwitz KL; Sibbing D; Kastrati A
    Thromb Haemost; 2014 Dec; 112(6):1190-7. PubMed ID: 25183544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY).
    Rangé G; Yayehd K; Belle L; Thuaire C; Richard P; Cazaux P; Barbou F; Köning R; Chassaing S; Teiger E; Berthier R; Decomis MP; Claudel JP; Delarche N; Brunel P; De Poli F; Dupouy P; Beygui F; Albert F; Collet JP; Montalescot G;
    Arch Cardiovasc Dis; 2014 Apr; 107(4):225-35. PubMed ID: 24794216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful Prasugrel Therapy for Recurrent Left Main Stent Thrombosis in a Clopidogrel Hyporesponder.
    Kim YS; Lee SR
    Tex Heart Inst J; 2015 Oct; 42(5):483-6. PubMed ID: 26504448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune thrombocytopenic purpura and myocardial infarction: a dilemma of management.
    Zaid G; Dawod S; Rosenschein U
    Isr Med Assoc J; 2013 Dec; 15(12):775-6. PubMed ID: 24449985
    [No Abstract]   [Full Text] [Related]  

  • 7. Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist.
    Azmoon S; Angiolillo DJ
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):232-42. PubMed ID: 22581463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention.
    Liang J; Wang Z; Shi D; Liu Y; Zhao Y; Han H; Li Y; Liu W; Zhang L; Yang L; Zhou Y
    Angiology; 2015 Apr; 66(4):319-25. PubMed ID: 24913197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized antiplatelet therapy: the wrong approach?
    Collet JP; Montalescot G
    Arch Cardiovasc Dis; 2013 Oct; 106(10):481-6. PubMed ID: 24080323
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug-specific thienopyridine resistance in patient with recurrent coronary stent thrombosis.
    Milicic D; Skoric B; Lovric D
    J Invasive Cardiol; 2009 Aug; 21(8):E157-60. PubMed ID: 19652267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).
    Cuisset T; Grosdidier C; Loundou AD; Quilici J; Loosveld M; Camoin L; Pankert M; Beguin S; Lambert M; Morange PE; Bonnet JL; Alessi MC
    JACC Cardiovasc Interv; 2013 Aug; 6(8):854-63. PubMed ID: 23968703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
    Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
    JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent acute coronary syndrome and restenosis after percutaneous coronary intervention in a patient with idiopathic thrombocytopenic purpura: a case report and literature review.
    Li-Sha G; Peng C; Yue-Chun L
    BMC Cardiovasc Disord; 2015 Sep; 15():101. PubMed ID: 26385102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
    Legrand V; Cuisset T; Chenu P; Vrolix M; Martinez C; Dens J; Gach O; Boland J; Claeys MJ; Magne J; Barbato E; Wijns W
    EuroIntervention; 2014 Jun; 10(2):204-11. PubMed ID: 24952058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future of oral antiplatelet therapy: four challenged hypotheses.
    Serebruany VL; Makarov LM
    Thromb Haemost; 2009 Jun; 101(6):1041-3. PubMed ID: 19492145
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
    Capranzano P; Mehran R; Tamburino C; Stone GW; Dangas G
    Hosp Pract (1995); 2010 Nov; 38(4):38-43. PubMed ID: 21068525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Point-of-care testing of clopidogrel-mediated platelet inhibition and risk for cardiovascular events after coronary angiography with or without percutaneous coronary intervention.
    Holm M; Dalén M; Tornvall P; van der Linden J
    Blood Coagul Fibrinolysis; 2014 Sep; 25(6):577-84. PubMed ID: 24614428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet therapy: Does prasugrel or ticagrelor suffice in patients with STEMI?
    Agrawal K; Bhatt DL
    Nat Rev Cardiol; 2013 Mar; 10(3):121-2. PubMed ID: 23319096
    [No Abstract]   [Full Text] [Related]  

  • 20. Telephone contact to improve adherence to dual antiplatelet therapy after drug-eluting stent implantation.
    Rinfret S; Rodés-Cabau J; Bagur R; Déry JP; Dorais M; Larose E; Barbeau G; Gleeton O; Nguyen CM; Noël B; Proulx G; Roy L; Taillon I; De Larochellière R; Bertrand OF;
    Heart; 2013 Apr; 99(8):562-9. PubMed ID: 23434769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.